Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The New Oncology Model Created to Improve Cancer Care

For anyone working in the oncology field, a highly anticipated change set to take place will be one of the biggest transitions in recent years. Last year, it was announced that the Oncology Care Model (OCM) will be phased out and succeeded with the Enhanced Oncology Model (EOM). This new model will go into effect…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Carevive on MarketScale.

Share
The New Oncology Model Created to Improve Cancer Care

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

For anyone working in the oncology field, a highly anticipated change set to take place will be one of the biggest transitions in recent years. Last year, it was announced that the Oncology Care Model (OCM) will be phased out and succeeded with the Enhanced Oncology Model (EOM). This new model will go into effect in July 2023 and help improve care for cancer patients.

What are the people who work in the oncology field most looking forward to with the forthcoming new model implementation? And what are their expectations for cancer care?

In the latest episode of “Oncology and Technology,” host Tyler Kern sat down to interview with several members of the Carevive team, John Elliot, VP of Sales; Reesa Sherin, Clinical Strategist; and April Boyd, Clinical Product Manager, mostly about the state of the oncology, and what current trends will remain or seeing advancements next year.

Kern, Elliot, Sherin, and Boyd also talked about …

  1. Educational events held in preparation for the shift to EOM
  2. What clinicians will value in terms of the new models and how they expect to implement
  3. How the shift will change oncology and cancer patient care

“The big shift, I think, just in healthcare broadly and then specifically to oncology, has been continued evaluation and how health systems and cancer centers are evaluating a shift to value-based care from the traditional … service,” said Elliot.

John Elliot is the Vice President of Sales at Carevive. He has been with the company for almost four years and held a previous senior position at Cerner Corporation. Elliot is a graduate of Southern Methodist University and Washington University in St. Louis – Olin Business School.

Reesa Sherin is Carevive’s Clinical Strategist and is a MSN and RN. She has been with the company for six years and is a graduate of Temple University and Thomas Jefferson University.

April Boyd is the Clinical Product Manager at Carevive and has been in that role for three years now. Prior to that she worked at the MD Anderson Cancer Center.

Carevive

Part of this channel

Carevive

Remote oncology monitoring that connects clinicians and cancer patients between visits.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

CMS Sets $90-$420 Per-Patient Payments for Chronic Care Tech

CMS Sets $90-$420 Per-Patient Payments for Chronic Care Tech

CMS's ACCESS payment model, fully active as of July 2026, pays companies $90 to $420 per Medicare beneficiary per year for technology-supported chronic care tied to outcomes, according to HFMA. The model also requires participants to connect through CMS-designated interoperability networks, and more tech companies than traditional providers have signed on so far.

  • 01CMS ACCESS model provides annual payments of $90 to $420 per Medicare beneficiary for chronic care supported by technology.
  • 02Payments in the ACCESS model range from $90 to $420 per beneficiary per year depending on whether specified outcome targets are met.
  • 03The initiative aims to promote the integration of technology in chronic care management.

Sep 10, 2026

Google’s AlphaGenome Atlas puts billions of DNA variants in reach

Google’s AlphaGenome Atlas puts billions of DNA variants in reach

AlphaGenome Atlas gives researchers predicted molecular effects for possible DNA changes across the human genome, helping teams prioritize variants for experimental follow-up.

  • 01The Atlas covers roughly nine billion possible single-letter DNA substitutions, according to The Verge.
  • 02Predictions can prioritize research questions but do not establish clinical findings.
  • 03The useful implementation pattern is prediction, study-specific evidence, then validation.

Sep 9, 2026

OpenAI put 10,000 AI agents on Navier–Stokes. Healthcare R&D should pay attention

OpenAI put 10,000 AI agents on Navier–Stokes. Healthcare R&D should pay attention

OpenAI says roughly 10,000 AI agents produced a proposed Navier–Stokes solution in 88 hours, followed by Lean verification. For healthcare and life sciences, the immediate signal is a research workflow built around parallel agents, code execution, provenance and formal checking—not a ready-made clinical simulator.

  • 01OpenAI's result is a proposed proof under review, not a new clinical simulation product.
  • 02The near-term B2B signal is a coordinated research stack combining agents, code and formal verification.
  • 03Healthcare buyers should evaluate provenance, reproducibility, security and cost per validated result.

Sep 9, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512